#LCSM chat 8/13 8pm ET: How can we fight the rising cost of cancer care?
Q A July 23 article in Newsweek titled “The High Cost of Cancer Care: Your Money or Your Life?” emphasizes a topic of increasing concern: the escalating costs of new cancer drugs, and the toll this takes on patients and families. A presentation at ASCO 2015 titled “Perspectives in Value” graphically showed the escalating price of cancer drugs in recent years, and how those prices soar off the charts for some new immunotherapies. The presentation also showed how prices of targeted therapy drugs don’t seem to go down as more patients use… Read More
#LCSM Chat Topic 6/4 8pm ET: Moving Ahead with Immunotherapy for Lung Cancer–Biomarkers, Timing, Duration, and Combinations
by H. Jack West, MD The hot subject at ASCO this year was immunotherapy for many cancers, and developments in lung cancer led the charge. The specific findings of greatest interest were that the PD-1 inhibitor Opdivo (nivolumab) was found to have a far superior survival, higher response rate, and overall better side effect profile than Taxotere (docetaxel) as second line treatment after initial chemotherapy. The US FDA approved Opdivo for squamous NSCLC, and we anticipate an approval for non-squamous NSCLC soon. But there are still several open questions as we integrate… Read More
#LCSM 
You must be logged in to post a comment.